-
Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial
•
China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical Products Administration (NMPA) to conduct a clinical trial of its HRG2101 inhaler for idiopathic pulmonary fibrosis (IPF). The drug, with no similar marketed products in China, targets fibroblast activity and inflammatory pathways to address the…
-
U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline
•
U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of millions of renminbi in Angel and Angel+ financing rounds. The funding, led by Shanghai Biomedical Industry Equity Investment Fund’s transformation fund and Zheshang Venture Capital, will accelerate development of its PROTAC and molecular glue drug…
-
J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”
•
Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched the “Love Nose e-Station” app, a digital rhinitis management platform, following their March 2022 partnership. The app offers end-to-end health management solutions for rhinitis patients, from prevention to treatment, aiming to boost disease awareness and…
-
Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy
•
Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies, announced the completion of a USD 50 million Series A-1 financing round. The funding, led by CD Capital, will support pre-clinical validation, clinical trials, and talent recruitment for its universal off-the-shelf CAR-NK pipeline. Financing DetailsThe…
-
Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris
•
US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for its preclinical drug candidate nepicastat, a small-molecule inhibitor of dopamine beta-hydroxylase (DBH). Asieris will develop the drug for non-psychiatric indications, with a focus on cardiovascular diseases linked to sympathetic nervous system overactivation. Deal TermsUnder the…
-
SAMR Issues New Rules for Online Drug Sales in China
•
China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and Administration of Online Drug Sales,” effective December 1, 2022. The 42-article regulation aims to ensure drug quality, safety, and accessibility, targeting online retailers, platforms, and prescription drug sales. Drug Operator ResponsibilitiesThe rules clarify qualifications for…
-
NMPA Designates Shijiazhuang Airport as Drug Import Port for Narcotics, Psychotropics
•
China’s National Medical Products Administration (NMPA) has designated Shijiazhuang Airport in Hebei Province as an official drug import port, following approval from the State Council. The move allows the import of select Chinese medicines, chemicals, narcotics, and psychotropic drugs through the airport. Port ResponsibilitiesThe Shijiazhuang market administration bureau has been…
-
Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC
•
Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market, with plans to launch a bridging study in H2 2022 for extensive-stage small-cell lung cancer (ES-SCLC). The decision follows a meeting with the U.S. FDA, as the firm seeks to replicate its Phase III success…
